|

Neratinib Clinical Trials

10 actively recruiting trials across 5 locations

▼ -1 trial since June 2026

Also known as: NERLYNX, Nerlynx

Pipeline

Phase 2: 8Phase 3: 1

Top Sponsors

  • University Health Network, Toronto2
  • Vanderbilt-Ingram Cancer Center1
  • UNICANCER1
  • Shu Wang1
  • Scott R. Plotkin, MD, PhD1

Indications

  • Cancer10
  • Breast Cancer6
  • HER2-positive Breast Cancer4
  • Non-vestibular Schwannoma1
  • Neurofibromatosis Type 21

Other4 trials

Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer
Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease
Phase 2
Personalized Medicine for Advanced Biliary Cancer Patients
Phase 3
Using Tumor Models to Determine Treatments
Phase 2

Birmingham, Alabama2 trials

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

University of Alabama at Birmingham

Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

University of Alabama at Birmingham

Phase 2

Los Angeles, California1 trial

Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)

UCLA Medical Center

Phase 2

Atlanta, Georgia1 trial

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Emory University/ Winship Cancer Institute

Phase 2

Chicago, Illinois1 trial

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

University of Illinois Cancer Center

Phase 2

Lebanon, New Hampshire1 trial

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor

Dartmouth Hitchcock Medical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.